Robbins Geller provides comprehensive securities fraud monitoring solutions for its clients who invest globally. By providing clients with the ability to identify and assess their losses associated with securities fraud, clients are given the information necessary to maximize their potential recoveries worldwide.
Robbins Geller was recently selected to advise the largest local authority pension fund in the United Kingdom, the £16 billion Greater Manchester Pension Fund, on corporate governance and shareholder actions. “We are pleased to have access to the expert advice of Robbins Geller. They have a long-proven track record of vigorously and effectively protecting shareholder rights and we value their input,” said Councillor Kieran Quinn, Executive Leader of Tameside Metropolitan Borough Council, Chair of Greater Manchester Pension Fund and Chair of Local Authority Pension Fund Forum. The fund won 2014 Large Scheme of the Year and also Best Member Communications Awards from Professional Pensions magazine.
Participants in Robbins Geller’s Portfolio Monitoring Program® receive a monthly Portfolio Monitoring Report and monthly Settlement Report. The Portfolio Monitoring Report provides information on U.S. securities class actions. The Settlement Report provides detailed information on U.S. and international settlements that have approaching claim deadlines.
Robbins Geller’s Portfolio Monitoring Program® is used all over the world by pension fund trustees, fund managers and institutional investors. The Firm currently monitors hundreds of institutional investor funds with more than $2 trillion in total assets.
Read More Firm News
- “Landmark” $650 Million Settlement in Facebook Biometric Class Action Approved as a “Major Win” for Consumers in the Area of Digital PrivacyFebruary 26, 2021
- February 17, 2021
- Robbins Geller’s Desiree Cummings Appointed to Plaintiffs’ Steering Committee in Blackbaud Data Breach MDLFebruary 17, 2021
- February 8, 2021
- Litigators of the Week: How Robbins Geller Landed a $1.2B Settlement in the Valeant Pharmaceuticals Securities CaseFebruary 5, 2021